Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2010

View Archived Issues

Clinical data from the evaluation of Debio-025 in HCV-infected patients disclosed

Recent data support safety and potentcy of HCV NS3 protease inhibitor ACH-1625

Positive modulators of nAChRalpha7 identified at NeuroSearch

Roche claims novel gamma-secretase inhibitors

Snapshots: new reports on biomarkers related to cardiovascular disorders

Novel tachykinin NK3 receptor antagonists identified at Roche

Tibotek discloses novel CYP450 inhibitors as boosters for anti-HIV agents

Novel protein kinase inhibitors presented by Priaxon

Secreted phospholipase A2 a potential marker of traumatic brain injury

Intraprostatic botulinum toxin type A improves signs and symptoms of BPH

Padeliporfin-mediated vascular targeted phototherapy promising in prostate cancer trial

REDUCE study clarifies effects of dutasteride in prostate cancer

First quarter events at Chugai

VaxInnate presents preliminary results from phase II study of VAX-125 flu vaccine

FDA approves once-daily dosing of Kaletra for previously treated HIV patients

Prana releases position statement on PBT-2 therapeutic strategy in Alzheimer's disease

Tarceva receives E.U. approval as maintenance treatment in advanced NSCLC

Takeda submits NDA for azilsartan medoxomil to treat hypertension in the U.S.

New biotechnology company, Immunovo, secures seed funding

New company LipimetiX created to focus on lipid-lowering treatments

FDA issues complete response letter for Giazo NDA

PolyMedix initiates phase Ib/II dose-ranging PMX-60056 study

Ceregene starts new phase I/II study of CERE-120 for Parkinson's disease

Johns Hopkins and the New York Stem Cell Foundation to collaborate on stem cell research

Dendreon receives FDA approval for Provenge for castrate-resistant prostate cancer

NexMed's NexACT technology improves delivery and activity of Angstrom's A6 anticancer compound

Hana Biosciences completes pre-NDA meeting with FDA for Marqibo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....